<!DOCTYPE html>
<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/
-->
<!--[if lt IE 7]>
<html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en">
<![endif]-->
<!--[if IE 7]>
<html class="no-js lt-ie9 lt-ie8" lang="en">
<![endif]-->
<!--[if IE 8]>
<html class="no-js lt-ie9" lang="en">
<![endif]-->
<!--[if gt IE 8]>
<!-->
<html class="no-js" lang="en">
<!--<![endif]-->

<head>
    <meta charset="utf-8" />
    <!-- Set the viewport width to device width for mobile -->
    <meta name="viewport" content="width=device-width" />
    <title>
        PracticeUpdate : Expert Opinion Item
    </title>
    <link rel="stylesheet" href="assets/css/app.css">
    <link rel="stylesheet" href="assets/css/font-awesome.css">
    <link rel="stylesheet" href="assets/css/fc-webicons.css">
    <link rel="stylesheet" href="assets/css/foundation-icons-general.css">
    <script src="assets/js/foundation/modernizr.foundation.js">
    </script>
    <!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js">
        </script>
    <![endif]-->
</head>

<body id="page" class="update off-canvas slide-nav expert-opinion-item logged-out">
    <div class="widget ad">
        <div id="leaderboard" class="Breast ad-container">
            <div class="ad-title">
                <span class="ad-title-text">
                    advertisement
                </span>
            </div>
            <!--/.ad-title-->
            <div id="leaderboardcontent" class="ad-content">
            </div>
            <!--.ad-content-->
        </div>
        <!--/#leaderboard.ad-container-->
    </div>
    <!--/.widget.ad-->
    <div class="page-header">
    </div>
    <!--/.page-header-->
    <div class="page-content">
        <section role="main">
            <div class="single-item-container">
                <article class="type-expert-opinion single-item">
                    <!-- info taken from: http://oncologystat.com/viewpoints/seminal_articles/Seminal_Articles_Germ_Cell_Tumors.html
                    -->
                    <div class="item-header-container">
                        <header class="item-header">
                            <div class="flag-container">
                                <span class="flag featured">
                                    <i class="icon-bolt">
                                    </i>
                                    featured
                                </span>
                                <span class="flag story-of-the-week">
                                    <i class="icon-bolt">
                                    </i>
                                    story of the week
                                </span>
                            </div>
                            <div class="meta pub-meta">
                                <span class="item-type">
                                    Seminal Article
                                </span>
                                <span class="item-pub-date">
                                    <time datetime="12-12-19">
                                        December 19, 2012
                                </span>
                            </div>
                            <hgroup class="item-title-container">
                                <h1 class="item-title">
                                    Seminal Articles—Growth Factor Support
                                </h1>
                                <p class="item-citation">
                                    <!-- {{source.citation}} -->
                                    2012 Mar 26, David Henry, MD, Editor: Amy Clark, MD
                                </p>
                            </hgroup>
                            <!-- /.item-title-container -->
                        </header>
                    </div>
                    <!--/.item-header-container-->
                    <div class="item-content-container">
                        <div class="item-content">
                            <div class="item-content-section">
                                <section class="seminal-article-body">
                                    <div class="seminal-article-body-container">
                                        <div class="source-container">
                                            <div class="vcard">
                                            </div>
                                            <!--/.vcard-->
                                        </div>
                                        <!--/.source-container-->
                                        <p>Based on our expert’s review, here are the must-read articles for every oncologist about use of growth factor support in patients with cancer.</p><p><strong>Use of White Cell Growth Factors in Solid Malignancies</strong></p><p>1. Burris HA, Belani CP, Kaufman PA, et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: results of four multicenter, double-blind, randomized phase II studies. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868638/?tool=pubmed">J Oncol Pract. 2010 May;6(3):133&ndash;140</a>. <strong>Free</strong></p><p>2. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <a target="_blank" href="http://jco.ascopubs.org/content/21/8/1431.full">J Clin Oncol. 2003 Apr 15;21:1431&ndash;1439</a>.</p><p>3. von Minckwitz G, Kümmel S, du Bois A, et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. <a target="_blank" href="http://annonc.oxfordjournals.org/content/19/2/292.long">Ann Oncol. 2008 Feb;19(2):292&ndash;298. Epub 2007 Sep 9</a>. <strong>Free</strong></p><p>4. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. <a target="_blank" href="http://jco.ascopubs.org/content/23/6/1178.long">J Clin Oncol. 2005 Feb 20;23(6):1178&ndash;1184</a>.</p><p>5. Timmer-Bonte J, de Boo T, Smit H, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. <a target="_blank" href="http://jco.ascopubs.org/content/23/31/7974.full.pdf">J Clin Oncol. 2005;23:7974&ndash;7984</a>.</p><p><strong>Use of Red Cell Growth Factors in Cancer</strong></p><p>6. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. <a target="_blank" href="http://jama.ama-assn.org/content/299/8/914.abstract?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fulltext=epoetin&amp;searchid=1&amp;FIRSTINDEX=0&amp;resourcetype=HWCIT">JAMA. 2008 Feb 27;299(8):914&ndash;924</a>.</p><p>7. Untch M, von Minckwitz G, Konecny GE, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/21382868">Ann Oncol. 2011 Sep;22(9):1999&ndash;2006. Epub 2011 Mar 7</a>.</p><p>8. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a metaanalysis of randomised trials. <a target="_blank" href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2960502-X/abstract">Lancet 2009;373:1532&ndash;1542</a>. Elsevier</p><p>9. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer: Meta-analysis based on individual patient data. <a target="_blank" href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007303.pub2/abstract;jsessionid=91BF1DC12679DF296C38C00C5DBB7305.d01t02">Cochrane Database Syst Rev 3:CD007303, 2009</a>.</p><p>10. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. <a target="_blank" href="http://jco.ascopubs.org/content/25/9/1027.full">J Clin Oncol. 2007;25:1027&ndash;1032</a>.</p><p>11. Henry DH, Parenteral iron therapy in cancer associated anemia. <a target="_blank" href="http://asheducationbook.hematologylibrary.org/content/2010/1/351.full.pdf+html">Hematol. 2010 December 4;1:351-356</a>. <strong>Free</strong></p><p>12. Glasby J. Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other outcomes. <a target="_blank" href="http://www.nature.com/bjc/journal/v102/n2/full/6605498a.html">Br J Cancer. 2010;102:301-315</a>. <strong>Free</strong></p><p>13. Ludwig, pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. <a target="_blank" href="http://jco.ascopubs.org/content/27/17/2838.abstract">J Clin Oncol 27:2838-2847</a>.</p><p><strong>Use of Growth Factors in MDS</strong></p><p>14. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/114/12/2393.full.pdf">Blood. 2009;114:2393&ndash;2400</a>. <strong>Free</strong></p><p>15. Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. <a target="_blank" href="http://www.springerlink.com/content/26518v5181118k63/">Ann Hematol. 2008;87:527&ndash;536</a>.</p><p>16. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/cgi/pmidlookup?view=long&amp;pmid=20631375">Blood. 2010 Oct 28;116(17):3163&ndash;3170</a>. <strong>Free</strong></p><p>17. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. <a target="_blank" href="http://hwmaint.jco.ascopubs.org/cgi/content/abstract/28/3/437">J Clin Oncol. 2010 Jan 20;28(3):437&ndash;444</a>.</p><p><strong>Use of Growth Factors in Lymphoproliferative Disorders</strong></p><p>18. Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. <a target="_blank" href="http://www.nature.com/leu/journal/v21/n4/full/2404562a.html">Leukemia. 2007;21:627&ndash;632</a>.</p><p><strong>Use of Growth Factors in Hematologic Malignancies</strong></p><p>19. Sierra J, Szer J, Kassis J, et al. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. <a target="_blank" href="http://www.mendeley.com/research/a-single-dose-of-pegfilgrastim-compared-with-daily-filgrastim-for-supporting-neutrophil-recovery-in-patients-treated-for-lowtointermediate-risk-acute-myeloid-leukemia-results-from-a-randomized-doubleblind-phase-2-trial/#cancer.">BMC Cancer. 2008 Jul 10;8:195</a>.</p><p>20. Doorduijn JK, van der HB, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. <a target="_blank" href="http://jco.ascopubs.org/content/21/16/3041.full.pdf">J Clin Oncol. 2003;21:3041&ndash;3050</a>.</p><p>21. Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. <a target="_blank" href="http://informahealthcare.com/doi/abs/10.1080/1042819031000103953">Leuk Lymphoma. 2003;44:1503&ndash;1508</a>.</p><p>22. Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. <a target="_blank" href="http://www.jco.org/cgi/pmidlookup?view=long&amp;pmid=20368566">J Clin Oncol. 2010 May 1;28(13):2239&ndash;2245</a>.</p><p>23. Straus DJ, Testa MA, Sarokhan BJ, et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. <a target="_blank" href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.22221/abstract;jsessionid=20575AABF639E08F684EDA5A5FD5BCD4.d01t02">Cancer. 2006 Oct 15;107(8):1909&ndash;1917</a>. <strong>Free</strong></p><p></p>
                                    </div>
                                    <!--/.seminal-article-body-container -->
                                </section>
                                <!-- /.seminal-article-body -->
                            </div>
                            <!-- ./item-content-section -->
                        </div>
                        <!-- ./item-content -->
                    </div>
                    <!-- /.item-conten-container -->
                    <hr />
                    <footer class="copyright item-footer">
                        <img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"
                        />
                        <p>
                            Copyright &copy; 2012 Elsevier
                        </p>
                    </footer>
            </div>
            <!--/.item-container-->
            <div class="recommended">
                <div class="recent">
                </div>
                <!--/.recent-->
                <div class="ad">
                    <img src="http://placehold.it/300x250" align="ad" title="ad" />
                </div>
            </div>
            <!--/.recommended-->
        </section>
        <!--/[role="main"]-->
        <section id="sidebar" role="complementary">
            <div class="dashboard">
                <div class="panel cta register">
                    <p>
                        <!-- Meet Our Experts -->
                        Become a member to customize this page.
                        <p>
                            <a class="button" href="#action-register">Register for free</a>
                </div>
                <!--/.panel.cta.register-->
                <div class="component user-console">
                </div>
                <!--/.component.user-console-->
                <div class="component user-topic">
                </div>
                <!--/.component.user-topic-->
                <div class="component topic-spotlight">
                </div>
                <!--/.component.topic-spotlight-->
                <div class="panel">
                    <img src="http://placehold.it/200x200" />
                    <p>
                        <!-- Meet Our Experts -->
                        Meet our Advisory and Editorial Boards comprised of physician editors
                        and world-renowned experts.
                        <p>
                </div>
            </div>
            <!--/.sidebar-->
        </section>
        <!--/.[role="complimentary"]-->
    </div>
    <!--/.page-content-->
    <footer class="page-footer">
    </footer>
    <!-- /.page-footer -->
    <!-- Included JS Files (Uncompressed) -->
    <script src="assets/js/foundation/jquery.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.accordion.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.alerts.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.buttons.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.forms.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.navigation.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.orbit.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.reveal.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tabs.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tooltips.js">
    </script>
    <script src="assets/js/foundation/jquery.placeholder.js">
    </script>
    <script src="assets/js/foundation/app.js">
    </script>
    <script src="assets/js/foundation/jquery.offcanvas.js">
    </script>
    <script src="assets/js/mustache.js">
    </script>
    <!-- Mustache - homepage feed template -->
    <script>
                    	<!--
	Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
	    $.get('assets/mustache/feed-item.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.stream-container').html(html);
	    });

	});

	<!--
	Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
	    $.get('assets/mustache/recent.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.recent').html(html);
	    });

	});

	<!--
	Mustache - homepage user - console template -->
	$.getJSON('content/json/user-console.json', function(data) {
	    $.get('assets/mustache/user-console.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-console').html(html);
	    });
	});

	<!--
	Mustache - homepage user - topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
	    $.get('assets/mustache/user-topic.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-topic').html(html);
	    });
	});

	<!--
	Mustache - homepage topic - spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
	    $.get('assets/mustache/topic-spotlight.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.topic-spotlight').html(html);
	    });
	});
</script>
</body>

</html>